
CROSS-VALIDATED RISK SCORES ADAPTIVE ENRICHMENT (CADEN) DESIGN

A PREPRINT

Svetlana Cherlin
Population Health Sciences Institute
Newcastle University
Ridley 1 Building
Newcastle upon Tyne, UK
svetlana.cherlin@newcastle.ac.uk

James M. S. Wason*
Population Health Sciences Institute
Newcastle University
Ridley 1 Building
Newcastle upon Tyne, UK
james.wason@newcastle.ac.uk

January 20, 2022

ABSTRACT

We propose a Cross-validated ADaptive ENrichment design (CADEN) in which a trial population is enriched with a subpopulation of patients who are predicted to benefit from the treatment more than an average patient (the sensitive group). This subpopulation is found using a risk score constructed from the baseline (potentially high-dimensional) information about patients. The design incorporates an early stopping rule for futility. Simulation studies are used to assess the properties of CADEN against the original (non-enrichment) cross-validated risk scores (CVRS) design that constructs a risk score at the end of the trial. We show that when there exists a sensitive group of patients, CADEN achieves a higher power and a reduction in the expected sample size, in comparison to the CVRS design. We illustrate the application of the design in a real clinical trial. We conclude that the new design offers improved statistical efficiency in comparison to the existing non-enrichment method, as well as increased benefit to patients. The method has been implemented in an R package *caden*.

Keywords Adaptive enrichment, Clinical trials, Cross-validation, Risks scores, Subgroup analysis

1 Introduction

Enrichment clinical trial designs address the issue of investigating treatments that only provide benefit to a subgroup of patients. When the biological pathway of the disease is well understood, predictive biomarkers (biomarkers that can predict the response to treatment) can be identified and the entry of patient is restricted based on these biomarkers. However, often the mechanism of disease is unclear and there are no known predictive biomarkers. In this case, restricting the entry to a specific subgroup of patients might lead to overlooking other subgroups that also benefit. This leads to loss opportunity for patient-benefit as well as reducing the market for the treatment.

Adaptive enrichment designs (AEDs) could overcome this limitation by allowing the trial to update the inclusion criteria at the interim analysis. AEDs start by enrolling all the eligible patients and then narrowing the enrolment of patients to a subgroup predicted to benefit from the experimental treatment, at the interim analysis. Thus, in the second stage, the entry is restricted to the patients who are predicted to benefit from the treatment. Properly constructed adaptive enrichment designs have benefits compared to fixed designs with respect to statistical properties [Wang *et al.* (2009)].

The subgroup of patients who are predicted to benefit from the treatment is often defined by a single binary or continuous biomarker. [Jones and Holmgren (2007)] considered a design where subjects are classified into a single binary biomarker-positive or biomarker-negative subgroup. At the interim analysis of the preliminary efficacy of the treatment, a decision is made on whether to recruit the overall population or the biomarker-positive group. [Parashar *et al.* (2016)] extended the design of [Jones and Holmgren (2007)] by allowing early efficacy stopping (stopping the trial if the

*Alternative address: MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

required cumulative response has been achieved) in either the unselected population or the biomarker-positive subgroup at the interim analysis, thus minimising the expected sample size. The design of [Tournoux-Facon *et al.* (2011)] also allows early stopping for efficacy based on assessing the heterogeneity of response between two subgroups as identified by a single binary biomarker. At the interim analysis, the subgroup in which the treatment effect is uncertain continues to stage 2. [Wang *et al.* (2018)] considered an enriched biomarker stratified design in which both biomarker-positive and biomarker-negative patients are selected into the trial with different probabilities, and a biomarker stratified design in which a (potentially expensive) biomarker is replaced by a low-cost alternative biomarker. When the predictive biomarker is continuous, it could be dichotomised to define two distinct subgroups. However, this requires pre-specification of an optimal dichotomisation threshold which is often unknown. [Wang *et al.* (2020)] and [Simon and Simon (2017)] considered adaptive enrichment designs for a single continuous biomarker with the cut-off threshold being seamlessly determined within the design.

These designs assume that the sub-populations are characterised by a known single binary or continuous biomarker. However, identifying a single biomarker requires knowledge and biological interpretation of the disease pathway which may not be available. The subgroup can also be defined by a collection of biomarkers. For example, [Simon and Simon (2013)] considered the adaptive enrichment design based on a pre-specified mapping of a space of covariate vector \mathbf{x} to a $\{0,1\}$ according to the probability of response for patients with \mathbf{x} . However, the design assumes that the mapping of the covariate vector \mathbf{x} is known. [Wang *et al.* (2007)] considered an adaptive enrichment design with a subgroup defined by a genomic (composite) biomarker, however the design does not address the issue of constructing the composite biomarker. [Joshi *et al.* (2020)] considered a three-stage adaptive enrichment trial that estimates the best subgroup via a trade-off between the size of the subgroup and the treatment effect in the subgroup. The subgroup was estimated after the first stage and then refined after the second stage based on the accumulated data from the two stages. In this design, a few methods for estimating the subgroup were compared: linear model, overlapping group LASSO [Zeng and Breheny (2016)], classification and regression trees [Brieman *et al.* (1984)], random forest [Brieman (2001)], and support vector machine [Cortes and Vapnik (1995)]. Though simpler (linear model-based) methods were found to perform better than more complex methods for moderate sample sizes and effect sizes, the approach was only evaluated on a low number of biomarkers (four biomarkers). [Xu *et al.* (2020)] proposed an adaptive subgroup-identification enrichment design that simultaneously searches for low-dimensional predictive biomarkers, identifies the subgroups with differential treatment effects, and modifies study entry criteria at interim analyses. However, the method assumes knowledge of potential predictive biomarkers which is not always available in practice. The method was also evaluated on a low number of biomarkers (four biomarkers).

With the recent advances in multi-omics technologies, an increasingly large numbers of biomarkers are becoming available. Several approaches that utilise high-dimensional data have been proposed, such as a family of adaptive signature designs. These include developing a signature from high-dimensional data and then using this signature to identify a subgroup of patients who are the most likely to benefit from the treatment. For example, the adaptive signature design [Freidlin and Simon (2005), Freidlin *et al.* (2010)] utilises the information from interaction tests between treatment and (separately) each covariate to develop a genetic signature that can identify a subgroup of patients who benefit from the treatment. In these methods, the development and validation of the signature are performed in a single trial. The adaptive signature design of [Zhang *et al.* (2017)] approximated the optimal subgroup on the basis of an arbitrary set of baseline covariates. Several extensions of the adaptive signature design have been proposed, such as adaptive threshold design, generalised adaptive signature design and adaptive signature design with subgroup plots [Antoniou *et al.* (2016)]. A compound covariate predictor approach [Matsui (2006), Matsui *et al.* (2012), Radmacher *et al.* (2002)] and risk scores approach [Cherlin and Wason (2020)] summarise the high-dimensional information into a single score for each patient which is subsequently used for identifying a subgroup of patients who benefit from the treatment. [Tian *et al.* (2014)] proposed a method for estimating interaction between covariates and treatment using modified covariates, thus eliminating the need to model the main effect of the covariates. However, these approaches perform a *post hoc* analysis of high-dimensional data rather than adaptively enriching the patient population at the interim analysis.

We propose a design that utilises the risk score method of [Cherlin and Wason (2020)] to adaptively enrich the trial with the sub-populations of interest. At the interim analysis, the treatment is evaluated in the overall trial population. If the treatment is found to be effective in the overall population of patients, the recruitment from the overall (unselected) population of patients continues until the planned sample size is reached, otherwise the method evaluates the treatment effect in the sensitive group. If the treatment effect is not found to be effective in the overall population of patients but it is found to be promising in the sensitive group, the trial population is enriched with the patients who are predicted to belong to the sensitive group (the prediction is based on the data from stage 1). The design incorporates stopping for futility (in the case where neither the overall treatment effect nor the promising effect in the subgroup is detected). The design is implemented in an open-source R package *cadem* (Cross-validated ADaptive ENrichment) [Cherlin and Wason (2021)].

The remainder of this article is organized as follows. The Methods section describes the CADEN design. In the Simulation Study section, we explore the operating characteristics of the CADEN designs for various simulation scenarios and compare it to the (non-enrichment) cross-validated risk scores (CVRS) design. In the Real Data Example section, we illustrate the application of the designs to real clinical trial data (the NOAH trial). Finally, we summarise our conclusions in the Discussion section.

2 Methods

2.1 Description of the model

We employ the modelling assumptions of the CRVS design [Cherlin and Wason (2020)] whereby the outcome is influenced by a subset of K unknown covariates which may be categorical or continuous (the sensitive covariates) though a generalised linear model. For example, for a binary outcome the model looks as follows:

$$\text{logit}(p_i) = \mu + \lambda t_i + \alpha_1 x_{i1} + \dots + \alpha_K x_{iK} + \gamma_1 t_i x_{i1} + \dots + \gamma_K t_i x_{iK}, \quad (1)$$

where p_i is the probability that the outcome for the i th patient is 1, μ is the intercept; λ is the treatment main effect which is independent of the covariates; t_i is the treatment that the i th patient receives ($t_i = 0$ for the control arm and $t_i = 1$ for the treatment arm); x_{i1}, \dots, x_{iK} are the values for the K unknown sensitive covariates; $\alpha_1, \dots, \alpha_K$ are the main covariate effects for the K covariates; $\gamma_1, \dots, \gamma_K$ are the treatment-covariate interaction effects for the K covariates. The model assumes that there might exist a subset of patients (the sensitive group) with a higher probability of response when treated with the new treatment compared to the control treatment. This would correspond to $\gamma_1, \dots, \gamma_K$ being non-zero.

2.2 Adaptive signature analysis

The adaptive signature analysis is based on the CVRS design of [Cherlin and Wason (2020)] in which risk scores within each patient i are constructed as sums of the associated covariates x_{ij} weighted by their estimated effects $\hat{\beta}_j$. For a binary outcome, the effects β_j could be estimated using the logistic regression:

$$\text{logit}(p_i) = \mu + \lambda t_i + \alpha_j x_{ij} + \beta_j t_i x_{ij}$$

For constructing the risk scores, the cross-validation procedure is used, in which the model is built using the training subset and the risk scores are constructed for the patients in the test subset. The risk scores are computed as $RS_i = \sum_j \hat{\beta}_j x_{ij}$, and then divided into two clusters that correspond to the sensitive and non-sensitive groups of patients. The division is done using the k -means clustering procedure with $k = 2$. The method is implemented in an R package *rapids* [Cherlin and Wason (2019)]. For full details, see [Cherlin and Wason (2020)].

2.3 Hypotheses testing

In the CADEN design we consider a dual-composite null hypothesis H_C [Wang and Hung (2013)] that states that there is no difference between the response rates in the treatment arms in the overall trial population and also no difference between the response rates in the treatment arms within the sensitive group (the sensitive group is obtained by applying the adaptive signature analysis as described in Section 2.2). The null hypothesis H_C can be represented as an intersect of the hypothesis H_O and H_S , i.e.

$$H_C = H_O \cap H_S \quad (2)$$

In (2), the H_O represents the hypothesis that there is no difference between the response rates in the treatment arms in the overall trial population. For a binary outcome, this could be evaluated using a test based on a normal approximation for the difference of two proportions (*prop.test* R function, two-sided). H_S represents the hypothesis that there is no difference between the response rates in the treatment arms within the sensitive group. For a binary outcome, this could be examined using Fisher's exact test (two-sided).

2.4 Stages of design

The CADEN design consists of two stages, as illustrated in Figure 1. In stage 1, N_1 patients are enrolled and randomised to an experimental arm or a control arm. At the end of stage 1, an interim analysis is performed to test the efficacy of the treatment compared to the control in the overall population, at a pre-specified significance level α_1 . If the test in the overall population meets the α_1 significance level then the trial proceeds into stage 2 by enrolling all patients (the "unselected" strategy, see Section 2.4.2). If the test in the overall population does not meet the α_1 significance

level then the trial proceeds by testing whether there is a subgroup of patients (sensitive group) that show a promising treatment effect. Here, a sensitive group is identified by applying the adaptive signature analysis (see Section 2.2). The treatment effect in the sensitive group is estimated as described in Section 2.4.1. We define the test in the sensitive group as promising if it meets the significance at α_2 level. Depending on the results of the test in the sensitive group, the design proceeds into stage 2 according to one of the mutually exclusive strategies “stop” or “enrichment”, as described in Sections 2.4.3 and 2.4.4, respectively.

2.4.1 Treatment effect in the sensitive group

For a binary outcome, the treatment effect in the sensitive group is estimated by fitting the following model:

$$\text{logit}(p_i) = \mu + \lambda t_i + \kappa s_i + \gamma t_i s_i, \quad (3)$$

where t_i is the treatment that the i th patient receives, s_i is the subgroup membership of the i th patient ($s_i = 1$ for the sensitive group and $s_i = 0$ for the non-sensitive group), μ is the intercept, λ is the treatment effect, κ is the subgroup effect and γ is the treatment-by-subgroup interaction effect. Let $\hat{\theta} = (\hat{\mu}, \hat{\lambda}, \hat{\kappa}, \hat{\gamma})$ be a vector of the estimated parameters of (3), then the estimate of the treatment effect in the sensitive group has the following form:

$$\hat{\kappa} + \hat{\gamma} \sim N(\mathbf{g}\hat{\theta}^T, \mathbf{g}\Sigma\mathbf{g}^T),$$

where $\mathbf{g} = (0, 0, 1, 1)$ and Σ is the variance-covariance matrix of $\hat{\theta}$. The statistic for the treatment effect in the sensitive group, $S = \mathbf{g}\hat{\theta}^T / \sqrt{\mathbf{g}\Sigma\mathbf{g}^T}$ has the standard normal distribution under H_S , that is $S \sim N(0, 1)$.

2.4.2 “Unselected” strategy

If at the interim analysis the treatment is found to be effective in the overall population at the significance level α_1 , then the recruitment continues from the overall (unselected) eligible population of patients, until the planned sample size N is reached. At the final analysis, the difference between the the treatment arms is evaluated in the overall population of patients. Additionally, a *post hoc* adaptive signature analysis is performed.

2.4.3 “Stop” strategy

If at the interim analysis the treatment is not found to be effective in the overall population at the significance level α_1 , and is also not found to be promising in the sensitive subgroup at the significance level α_2 then the trial stops for futility.

2.4.4 “Enrichment” strategy

It might happen that at the interim analysis the treatment is not found to be effective in the overall population at the significance level α_1 but is found to be promising in the sensitive subgroup at the significance level α_2 .

In this case, the trial is enriched with the patients who are predicted to belong to the sensitive group, i.e. only patients who are predicted to belong to the sensitive subgroup are recruited for stage 2. First, the model M for computing the risk scores is obtained from the adaptive signature analysis performed on the data from stage 1 as described in Section 2.2.

Model M includes the vector of the coefficients $\hat{\beta}$ for computing the risk scores, and the means of the sensitive and the non-sensitive clusters of the risk scores (m_S and m_N , respectively).

Note, that when applying the adaptive signature analysis to stage 1 to obtain model M , the cross-validation technique is not required, because model M will be applied to the new data. Then for every new patient the following steps are performed:

- (a) Predicted sensitivity status is computed based on model M ;
- (b) The patient is randomised to either the control or treatment arm with the ratio 1:1 if they are predicted to belong to the sensitive subgroup, otherwise they will not be eligible to take part in the trial;
- (c) Steps (a) and (b) are performed until the planned sample size N is reached.

In (a), the risk score r for a new patient with covariate data \mathbf{x} is computed based the coefficients $\hat{\beta}$ from model M as $r = \mathbf{x} \times \hat{\beta}^T$. The sensitivity status of a new patient is predicted according to the distance between their risk score and the cluster means m_S and m_N from model M . The new patient is predicted to belong to the sensitive group if $m_S - r < m_N - r$, i.e. if the risk score for this patient is close to the mean of the sensitive cluster.

3 Simulation study

3.1 Simulation settings

We consider three simulation settings. In setting (i), we assume that there is no overall treatment effect and also no main effect of the covariates. However, there exists a sensitive group of patients for whom the interaction effect between treatment and sensitive covariates increases the probability of the response to treatment. Within this setting, we consider scenarios with different response rates in the sensitive group, and also different sample sizes. Setting (ii) corresponds to a null scenario in which the sensitive group does not exist. Within this setting, we consider a scenario where the response rate is the same for the entire trial population, and a scenario where there is an overall treatment effect. In setting (iii) we consider the situation where the treatment appears to be harmful for some patients. In this setting, we analyse two scenarios. In both scenarios, there is a subgroup of patients with a negative treatment-covariate interaction effect for some covariates, so that the response rate for this subgroup is lower than that for the control. In the second scenario, there is also a sensitive group, i.e a subgroup of patients with positive treatment-covariate interaction effect for the sensitive covariates. In both scenarios, we assume that there is no overall treatment effect and also no main effect of the covariates. See Appendix A and Table 4 for details of how the data were simulated.

3.2 Operating characteristics

We perform 1,000 runs for each simulation scenario and compute three types of statistical power. The first power hereafter referred to as PWR_O is the power to reject H_O when H_O is not true, that is the power to detect a difference in response rates between the treatment arms at the significance level α_O when the difference is indeed present. It is computed as a proportion of simulation runs with $p < \alpha_O$.

The second power hereafter referred to as PWR_S is the power to reject H_S when H_S is not true, that is the power to detect a difference in response rates between the treatment arms in the sensitive group at the significance level α_S for the “unselected strategy, or at the significance level α for the “enrichment” strategy, where $\alpha = \alpha_O + \alpha_S$. PWR_S is computed as a proportion of simulation runs where the sensitive subgroup hypothesis is tested and rejected.

The third power, hereafter referred to as PWR_C is the power to reject the dual-composite hypothesis H_C when H_C is not true, that is the power to detect either a difference between the arms in the overall population or in the sensitive group. In other words, PWR_C is the power to reject either null hypothesis H_O or H_S . It could be interpreted as the power to conclude that the trial is positive. PWR_C is computed as the proportion of simulations in which one of H_O or H_S is rejected.

Additionally, for each simulation scenario, we estimate the sensitivity and specificity of the design to predict the membership in the sensitive group of patients, and the expected sample size. The expected sample size, N_{exp} , is computed as

$$N_{exp} = N_1 \times \eta_s + (N_1 + N_2) \times (1 - \eta_s)$$

where η_s is the proportion of the simulation runs that follow the “stop” strategy.

3.3 Simulation results

Table 1 presents the results for the simulation setting (i) in which there exists a sensitive group of patients. Here, we analyse scenarios with different sample sizes (400 and 1000) and different response rates for the sensitive group on treatment (50%, 60% and 70%). For each case, we investigate three thresholds for α_2 (0.05, 0.1 and 0.2), the significance level for identifying a promising treatment effect in the sensitive group at the interim analysis. The sensitivity and specificity of identifying the sensitive group is high, reaching values of larger than 0.9 in most cases. As expected, the power is larger for a larger sample size and for a higher response rate in the sensitive group. For the same sample size and the same response rate in the sensitive group, the power increases as α_2 increases because increasing α_2 increases the probability of the design to follow the “enrichment” strategy. For example, with a sample size 1000 and a 50% response rate in the sensitive group, the power to reject the dual-composite null hypothesis (P_C) is 0.645, 0.694 and 0.764 for $\alpha_2 = 0.05, 0.1$ and 0.2 , respectively, while for the 60% response rate in the sensitive group P_C is 0.895, 0.926 and 0.94.

Table 2 presents the results for simulation setting (ii) in which there is no sensitive group. In this setting, we consider two scenarios: scenario A (a null scenario), where the response rate for everyone is 25%, and scenario B where everyone benefits equally from the treatment (the response rates are 25% and 35% on the control and the treatment arms, respectively). For scenario A, the power for rejecting the dual-composite null hypothesis (P_C) is less than 0.05 which means that the type I error rate is well controlled. For scenario B, P_C is around 0.3 due to the fact that there is a difference between the treatment groups in the overall population. The sensitivity and the specificity of identifying

the sensitive group is around 0.5 for both scenarios which reflects the fact that there is no true underlying sensitive group. Additionally, the reduction in the expected sample sizes ranges between 32%-42% for scenario A and between 24%-31% for scenario B, in comparison to the maximum sample size.

We also compare the performance of the CADEN design with the CVRS design for three different scenarios (Table 3). In scenario A, there exists a sensitive group of patients who benefit from the treatment more than everyone else. In this scenario, the response rate for the sensitive group on treatment is 60%, the prevalence of the sensitive group is 20%, and the response rate for the non-sensitive patients on treatment and for everyone in the control arm is 25%. The power to reject H_S , as well as the power to reject H_C are higher for the CADEN in comparison to CVRS, despite the expected required sample size being smaller, which shows the benefits of the "enrichment" strategy. The power to reject H_O is smaller for the CADEN design because the design less commonly proceeds according to the "unselected" strategy. In Scenario B, the treatment appears to be harmful rather than beneficial for the sensitive group that comprises 20% of patients (the response rate for the sensitive group on treatment is 10%, while the response rate for everyone else is 25%). Low values of the sensitivity and specificity reflect the fact that the "non-sensitive group" is actually the sensitive group that experiences higher benefit from the treatment (although there is no benefit compared to control). The expected required sample size and the power for CADEN is smaller than that for the CVRS which is desirable for this scenario. The power to conclude that the trial is positive which represents the type 1 error rate in this scenario (P_C) is lower for CADEN in comparison to CVRS. Also, the expected sample size is smaller. In scenario C, we assume that there is a sensitive group of patients with a prevalence of 20% which benefits from the treatment (the response rate is 40%). In addition to the sensitive group, there is another group of patients with a prevalence of 20% who experience harmful effects to treatment (the response rate is 10%). As with scenario B, the expected sample size for the CADEN design is smaller than that for the CRVS design which is again a desirable outcome given the fact that the treatment is harmful for some patients. Although the power to conclude that the trial is positive (P_C) is slightly higher for the CADEN design, it is still relatively low (less than 0.25). A high sensitivity and a low specificity for both the CADEN and the CVRS designs reflect the fact that the underlying design assumes the existence of two groups (sensitive and non-sensitive) while in reality there are three groups (sensitive, non-sensitive and a group with a harmful effect). In this situation the true sensitive group is well identified, while the non-sensitive group is not.

4 Real data example


We applied our approach to a publicly available dataset with high-dimensional gene expression biomarker data from the randomised controlled trial NOAH [Gianni *et al.* (2010)]. The trial enrolled 235 patients with HER2-positive locally advanced breast cancer, 117 of whom treated with neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab, and the rest (118 patients) treated with neoadjuvant chemotherapy alone. The primary outcomes of the trial were pathological complete response and event-free survival. We used the pathological complete response as the binary response endpoint.

Gene expression data from core biopsies that were prospectively collected before treatment, are available for 114 HER2-positive patients from the National Center for Biotechnology Information (NCBI) website (GSE50948), of whom 111 had the response data recorded. Of the 111 patients, 60 patients were in the treatment group, and the remaining 51 patients were in the control group. From a total of 54,675 genes, we restricted our analysis to the 5,000 probes with the highest variability, to adjust for the relatively small sample size [Freidlin *et al.* (2010)]. For the same consideration, we analysed the 111 patients as if they belonged to a stage 1 of a hypothetical two-stage trial. For the hypothetical stage 2, we repeatedly sampled 111 patients with replacement from the original pool of patients. Analysis of stage 1 resulted in the "unselected" strategy decision ($p = 0.03$ for the difference between the arms in the overall trial population). To sample patients for stage 2, we performed 1,000 runs with different seeds for random number generator, resulting in different set of patients for every run. The power for the final analysis was computed as the proportion of runs with significant p -values. The final analysis identified a significant difference between the treatment arms in the overall population ($PWR_O = 0.944$) and a significant treatment effect in the sensitive group of patients ($PWR_S = 1$) which resulted in high power to reject the dual-composite null hypothesis ($PWR_C = 1$). To compare the CADEN design with the CVRS design, we applied the CVRS method to 1,000 data sets. Each data set consisted of 222 patients, of whom 111 were the original patients, and another 111 were repeatedly sampled with replacement from the original pool of patients for the stage 2 of the CADEN analysis. This resulted in the same power as that for the CADEN analysis.

5 Discussion

Adaptive enrichment designs have the potential to improve the efficiency of clinical trials by enriching the trial population with a subgroup of patients that could benefit from the treatment more than average (the sensitive group). Several statistical approaches have been proposed so far in the literature for identifying the sensitive group using biomarker

Figure 1: The flowchart of the design



data. Here, we presented an adaptive enrichment design that identifies the sensitive group based on (potentially high-dimensional) baseline data. Specifically, the design considers enriching the recruitment with patients who are predicted to benefit from the treatment, based on their baseline covariates. The design includes early stopping for futility if no promising treatment effect is identified in the sensitive group and also the difference between the arms in the overall trial population is not significant. The sensitive group is identified using the risk score approach where each patient is assigned a score constructed from their baseline covariates. We have provided a freely available R package that implements the method. We have investigated the performance of the CADEN by applying it to simulated data scenarios with various response rates for the sensitive group and different sample sizes. As expected, the power increased with the increase of the sample size and/or the response rate in the sensitive group due to the fact that the probability of identifying a promising effect in the sensitive group increases.

We compared the performance of the CADEN design to the non-enrichment CVRS design. We showed that the CADEN design has higher power in comparison to the CVRS design. The CADEN design allows to narrow down the eligibility and also achieves this at a smaller expected sample size, in comparison to the CVRS design. For the null scenario, the CADEN design achieves a well-controlled type I error rate with a substantial reduction in the expected sample size which is a desirable outcome when the sensitive group does not exist. To investigate the behaviour of the design for model misspecification, we analysed scenarios where there exists a subgroup of patients for whom the treatment

appears to be harmful. As with the null scenario, the expected sample size is substantially reduced which is again a desirable outcome in these cases. Regarding the power, the CADEN design behaves similarly to the non-enrichment CVRS design.

We investigated different values for the threshold for the significance level of identifying the promising treatment effect in the sensitive group at the interim analysis ($\alpha_2 = 0.05, 0.1$ and 0.2). A larger threshold improves on the power for identifying the treatment effect in the sensitive group. However, when the sensitive group does not exist, increasing the threshold increases the type I error rate. We suggest incorporating a prior belief regarding the existence of the sensitive group into the consideration for choosing the values of α_2 , and propose that this issue constitutes a part of further research.

We illustrated our approach on the randomised clinical trial NOAH with publicly available high-dimensional gene expression data. However, owing to a relatively small sample size of the trial we sampled an additional set of patients from the trial population. At the final analysis, we identified a sensitive group of patients with a significant treatment effect. At the interim analysis, the decision was to follow the “unselected” strategy because of a significant difference between the treatment arms in the overall trial population. We note that if the trial had proceeded according to the “enrichment” strategy, performing the gene expression profiling would have had to have been done quickly to ensure the smooth running of the trial. Alternatively, there could have been a run-in period prior to the enrolment of patients. An additional caveat would be assessing the impact of the potential misclassification of a genomic classifier that might have lead to a wrong subgroup prediction of patients [Wang *et al.* (2011)].

To compute the power to reject the dual-composite null hypothesis H_C , we split the significance level $\alpha = 0.05$ into two parts: $\alpha_O = 0.04$ (for the power to reject H_O), and $\alpha_S = 0.01$ (for the power to reject H_S). This split was motivated by the work of [Freidlin and Simon (2005)] and [Freidlin *et al.* (2010)] who considered 0.04 and 0.01 for the overall and within-the-subgroup power for the non-enrichment adaptive signature design. Future work will include investigating a number of methods for assigning weights to the statistical significance levels associated with the H_O and H_S hypotheses in order to improve the statistical efficiency of the design [Sugitani *et al.* (2018)]. Additionally, further research could be focused on investigating alternative clustering approaches and different distributions of outcomes, as well as multiple endpoints [Cherlin and Wason (2021)].

6 Appendix A

In the simulation study, the data were simulated as follows:

1. Simulate the baseline covariates according to the following: for sensitive covariates in the sensitive group, using a multivariate normal distribution with mean $\mu_1 = 1$, variance $\sigma_1^2 = 0.25$, and correlation $\rho_1 = 0$; for sensitive covariates in the non-sensitive group, using a multivariate normal distribution with mean $\mu_2 = 0$, variance $\sigma_2^2 = 0.01$, and correlation $\rho_2 = 0$; for nonsensitive covariates in all patients, using a multivariate normal distribution with mean $\mu_0 = 0$, variance $\sigma_0^2 = 0.25$, and correlation $\rho_0 = 0$; for sensitive covariates in the group that experience harmful effect on treatment, using a multivariate normal distribution with mean $\mu_3 = -1$, variance $\sigma_3^2 = 0.25$, and correlation $\rho_3 = 0$.
2. For each subject, compute linear predictors ω according to (1). The required parameters for computing ω_i are obtained as follows:
 - (a) Set $\alpha_1, \dots, \alpha_K = 0$ and $\lambda = 0$, where $k = 1, \dots, K$ are the indices of the sensitive covariates.
 - (b) Compute μ so that it corresponds to a 25% response rate on the control arm, i.e. $\mu = \log(0.25/0.75)$.
 - (c) Compute $\gamma_1, \dots, \gamma_K$ so that they correspond to the desirable response rate in the sensitive group on treatment, RR , i.e.

$$\gamma_k = \frac{\log\left(\frac{RR}{1-RR}\right) - \mu}{K}.$$

3. Compute the probability of response as $p = \exp(\omega)/(1 + \exp(\omega))$.
4. Assign response to each subject using Bernoulli distribution with parameter p .

References

[Antoniou *et al.* (2016)] Antoniou M *et al.* (2016) *Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review*, PLoS ONE 11:p.e0149803. doi: 10.1371/journal.pone.0149803

Table 1: Operating characteristics of the adaptive risk scores enrichment (CADEN) design for the following scenario: the response rate on the control arm is 25%. The response rate for the sensitive group on the treatment arm are 50%, 60% and 70%. The response rate for non-sensitive patients on the treatment arm is 25%. The prevalence of the sensitive patients is 10%. The sample sizes for each stage are equal to a half of the overall sample size. Ten covariates out of 100 are sensitive. The results, as based on 1000 simulations, are presented for thresholds $\alpha_2 = 0.05/0.1/0.2$ for the treatment effect in the sensitive group at the interim analysis. PWS_O is the power to reject H_O (a null hypothesis that there is no difference between the treatment arms in the overall trial population). PWS_S is the power to reject H_S (a null hypothesis that there is no difference between the treatment arms within the sensitive subgroup). The power to conclude that the trial is positive, PWR_C , is the power to reject a dual-composite hypothesis H_C which is the power to reject either null hypothesis H_O or H_S . N_{exp} denotes the expected sample size.

Operating characteristics	Response rate in the sensitive group		
	50%	60%	70%
Sample size = 400			
PWR_O	0.02/0.01/0.02	0.03/0.03/0.02	0.04/0.04/0.05
PWR_S	0.22/0.28/0.33	0.41/0.48/0.58	0.57/0.66/0.75
PWR_C	0.23/0.28/0.35	0.41/0.48/0.58	0.56/0.65/0.74
Sensitivity	0.92/0.92/0.92	0.96/0.97/0.96	0.99/0.99/0.98
Specificity	0.8/0.81/0.81	0.87/0.88/0.88	0.92/0.93/0.93
% unselected	4.5/4.5/4.5	5.4/5.4/5.4	8/8/8
% enrichment	26.5/34.7/46.2	39.5/47.4/59.2	52.7/61/70.5
% stop	69/60.8/49.3	55.1/47.2/35.4	39.3/31/21.5
N_{exp}	262/279/302	290/306/330	322/338/357
Sample size = 1000			
PWR_O	0.03/0.04/0.04	0.08/0.08/0.08	0.14/0.15/0.14
PWR_S	0.61/0.67/0.75	0.88/0.91/0.93	0.99/0.98/0.99
PWR_C	0.6/0.67/0.74	0.85/0.89/0.9	0.93/0.94/0.94
Sensitivity	0.98/0.97/0.97	0.99/0.99/0.99	0.99/1/1
Specificity	0.95/0.98/0.99	0.99/0.99/0.99	1/0.99/0.99
% unselected	7.1/7.1/7.1	11.7/11.7/11.7	19.7/19.7/19.7
% enrichment	57.2/77/79.1	77/80.3/79.3	79.1/82.1/79.7
% stop	35.7/29.8/21.6	11.3/8/6.2	1.2/1/0.6
N_{exp}	822/851/892	994/960/969	994/995/997

[Brieman *et al.* (1984)] Brieman L *et al.*(1984) *Classification and regression trees*, Chapman and Hall/CRC. New York.ISBN 10: 0412048418

[Brieman (2001)] Brieman L (2001) *Random forests*, Machine Learning 45:5-32. doi: 10.1023/A:1010933404324

[Cherlin and Wason (2019)] Cherlin S and Wason JMS (2019) *Rapids*, GitHub repository <https://github.com/svetlanache/rapids>

[Cherlin and Wason (2021)] Cherlin S and Wason JMS (2021) *Caden*, GitHub repository <https://github.com/svetlanache/caden>

[Cherlin and Wason (2020)] Cherlin S and Wason JMS (2020) *Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores*, Statistics in Medicine 39:3285-3298. doi: 10.1002/sim.86654

[Cherlin and Wason (2021)] Cherlin S and Wason JMS (2021) *Developing a predictive signature for two trial endpoints using the cross-validated risk scores method*, Biostatistics. doi: 10.1093/biostatistics/kxaa055

[Cortes and Vapnik (1995)] Cortes C and Vapnik V (1995) *Support-vector networks*, Machine Learning 20:273-297. doi: 10.1007/BF00994018

[Freidlin *et al.* (2010)] Freidlin B *et al.* (2010) *The cross-validated adaptive signature design*, Clinical Cancer Research 16:691-698. doi: 10.1158/1078-0432.CCR-09-1357

[Freidlin and Simon (2005)] Freidlin B *et al.* (2010) *Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients*, Clinical Cancer Research 11:7872-7878. doi: 10.1158/1078-0432.CCR-05-0605

[Freidlin *et al.* (2014)] Freidlin B *et al.* (2014) *Marker Sequential Test (MaST) design*, Clinical Cancer Research 11:19-27. doi: 10.1177/1740774513503739

Table 2: Operating characteristics of the adaptive risk scores enrichment (CADEN) design for the scenarios where there is no sensitive group. The response rate on the control arm is 25%. Ten covariates out of 100 are sensitive. The results are based on 1000 simulations. Sample sizes are 200 for stage 1 and 200 for stage 2. The results are presented for thresholds $\alpha_2 = 0.05/0.1/0.2$ for the treatment effect in the sensitive group at the interim analysis. PWR_S is the power to reject H_0 (a null hypothesis that there is no difference between the treatment arms in the overall trial population). PWR_C is the power to reject H_S (a null hypothesis that there is no difference between the treatment arms within the sensitive subgroup). The power to conclude that the trial is positive, PWR_C , is the power to reject a dual-composite hypothesis H_C which is the power to reject either null hypothesis H_0 or H_S . N_{exp} denotes the expected sample size.
 Scenario A: The response rate for everyone on both arms is 25% (null scenario).
 Scenario B: The response rate for everyone on the treatment arm is 35%.

Scenario	Operating characteristics	$\alpha_2 = 0.05/0.1/0.2$
A	PWR_O	0.01/0.01/0.01
	PWR_S	0.01/0.01/0.02
	PWR_C	0.02/0.02/0.03
	Sensitivity	0.47/0.47/0.47
	Specificity	0.49/0.49/0.49
	% unselected	3.1/3.1/3.1
	% enrichment	13.1/21.4/32.7
	% stop	83.8/75.5/64.2
	N_{exp}	233/249/272
B	PWR_O	0.24/0.24/0.24
	PWR_S	0.09/0.12/0.13
	PWR_C	0.27/0.29/0.32
	Sensitivity	0.63/0.59/0.58
	Specificity	0.57/0.56/0.56
	% unselected	28.5/28.5/28.5
	% enrichment	9.7/15.2/23.4
	% stop	61.8/56.3/48.1
	N_{exp}	277/288/304

- [Gianni *et al.* (2010)] Gianni L *et al.* (2010) *Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort*, *Lancet* 375:377-384. doi: 10.1016/S0140-6736(09)61964-4
- [Jones and Holmgren (2007)] Jones CL and Holmgren E (2007) *An adaptive Simon two-stage design for phase 2 studies of targeted therapies*, *Contemporary Clinical Trials* 28:654-661. doi: 10.1016/j.cct.2007.02.008
- [Joshi *et al.* (2020)] Joshi N *et al.* (2020) *Multi-stage adaptive enrichment trial design with subgroup estimation*, *Journal of Biopharmaceutical Statistics* 30:1038-1049. doi: 10.1080/10543406.2020.1832109
- [Lai *et al.* (2019)] Lai T *et al.* (2019) *Adaptive enrichment designs for confirmatory trials*, *Statistics in Medicine* 8:613-624. doi: 10.1002/sim.7946
- [Matsui (2006)] Matsui S (2006) *Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays*, *BMC Bioinformatics* 7:156. doi: 10.1186/1471-2105-7-156
- [Matsui *et al.* (2012)] Matsui S *et al.* (2012) *Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine*, *Clinical Cancer Research* 18:6065-6073. doi: 10.1158/1078-0432.CCR-12-1206
- [Ondra *et al.* (2019)] Ondra T *et al.* (2019) *Optimized adaptive enrichment designs*, *Statistical Methods in Medical Research* 28:2096-2111. doi: 10.1177/0962280217747312
- [Parashar *et al.* (2016)] Parashar D *et al.* (2016) *An optimal stratified Simon two-stage design*, *Pharmaceutical Statistics* 5:333-340. doi: 10.1002/pst.17422
- [Radmacher *et al.* (2002)] Radmacher M *et al.* (2002) *A paradigm for class prediction using gene expression profiles*, *Journal of Computational Biology* 9:404-511. doi: 10.1089/106652702760138592
- [Simon and Simon (2013)] Simon N and Simon R (2013) *Adaptive enrichment designs for clinical trials*, *Journal of Biostatistics* 14:613-625. doi: 10.1093/biostatistics/kxt010

Table 3: Comparison of the cross-validated adaptive enrichment (CADEN) design with the CVRS design. The response rate on the control arm is 25%. Ten covariates out of 100 are sensitive. For CADEN, the results as presented for thresholds $\alpha_2 = 0.05/0.1/0.2$ for the treatment effect in the sensitive group at the interim analysis. PWR_O is the power to reject H_O (a null hypothesis that there is no difference between the treatment arms in the overall trial population). PWR_S is the power to reject H_S (a null hypothesis that there is no difference between the treatment arms in the sensitive subgroup). The power to conclude that the trial is positive, PWR_C , is the power to reject a dual-composite hypothesis H_C which is the power to reject either null hypothesis H_O or H_S . N_{exp} denotes the expected sample size. The results are based on 1000 simulations.

Scenario A: The response rate for the sensitive group on the treatment arm is 60%, the response rate for non-sensitive patients on the treatment arm is 25%. The prevalence of the sensitive patients is 20%. Sample size is 400 for CVRS, 200 for each stage of CADEN.

Scenario B: The treatment appears to be harmful for 20% patients (response rate 10%), the response rate for the rest of the patients on the treatment arm is 25%. Sample size is 1000 for CVRS, 500 for each stage of CADEN.

Scenario C: The response rate for the sensitive group on the treatment arm is 40%, the response rate for non-sensitive patients on the treatment arm is 25%. The prevalence of the sensitive patients is 20%. There are 20% of patients with a response rate of 10% on the treatment arm. Sample size is 1000 for CVRS, 500 for each stage of CADEN.

Scenario	Operating characteristics	CADEN $\alpha_2 = 0.05/0.1/0.2$	CVRS
A	PWR_O	0.1/0.11/0.11	0.28
	PWR_S	0.76/0.79/0.85	0.67
	PWR_C	0.74/0.78/0.83	0.77
	Sensitivity	0.97/0.98/0.97	0.99
	Specificity	0.94/0.96/0.96	1.00
	N_{exp}	358/364/0.375	400
B	PWR_O	0.05/0.05/0.06	0.15
	PWR_S	0.02/0.01/0.02	0.01
	PWR_C	0.06/0.07/0.08	0.16
	Sensitivity	0.04/0.04/0.04	0.02
	Specificity	0.06/0.06/0.06	0.01
	N_{exp}	800/846/895	1000
C	PWR_O	0.01/0.01/0.01	0.03
	PWR_S	0.16/0.2/0.23	0.14
	PWR_C	0.16/0.2/0.23	0.17
	Sensitivity	1.00/1.00/0.992	0.99
	Specificity	0.53/0.52/0.62	0.62
	N_{exp}	792/853/910	1000

Table 4: Response rate, prevalences and the sample sizes used in simulation study. RR_1 : response rate in the sensitive group on the treatment arm. RR_2 : response rate in the non-sensitive group on the treatment arm. RR_0 : response rate in all patients on the control arm. RR_3 : response rate in the subgroup of patients who experience a harmful effect on the treatment arm. $Prev$: Prevalence of the sensitive group and /or a group with a harmful effect on the treatment arm. $Sample$: The sample size of the trial.

Setting	Table	Scenario	RR_1	RR_2	RR_0	RR_3	Prev	Sample
i	1	-	0.5	0.25	0.25	-	0.1	400
i	1	-	0.6	0.25	0.25	-	0.1	400
i	1	-	0.7	0.25	0.25	-	0.1	400
i	1	-	0.5	0.25	0.25	-	0.1	1000
i	1	-	0.6	0.25	0.25	-	0.1	1000
i	1	-	0.7	0.25	0.25	-	0.1	1000
i	3	A	0.6	0.25	0.25	-	0.2	400
ii	2	A	0.25	0.25	0.25	-	-	400
ii	2	B	0.35	0.35	0.25	-	-	400
iii	3	B	0.25	0.25	0.25	0.1	0.2	1000
iii	3	C	0.4	0.25	0.25	0.1	0.2	100

- [Simon and Simon (2017)] Simon N and Simon R (2017) *Inference for multimarker adaptive enrichment trials*, *Statistics in Medicine* 36:4083-4093. doi: 10.1002/sim.7422
- [Sugitani *et al.* (2018)] Sugitani T *et al.* (2018) *Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup*, *Statistics in Medicine* 37:3387-3402. doi: 10.1002/sim.7851
- [Tian *et al.* (2014)] Tian L *et al.* (2014) *A simple method for estimating interactions between a treatment and a large number of covariates*, *Journal of the American Statistical Association* 109:1517-1532. doi: 10.1080/01621459.2014.951443
- [Tournoux-Facon *et al.* (2011)] Tournoux-Facon C *et al.* (2011) *How a new stratified adaptive phase II design could improve targeting population*, *Statistics in Medicine* 30:1555-1562. doi: 10.1002/sim.4211
- [Wang *et al.* (2007)] Wang S-J *et al.* (2007) *Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset*, *Pharmaceutical Statistics* 6:227-244. doi: 10.1002/pst.300
- [Wang *et al.* (2009)] Wang S-J *et al.* (2009) *Adaptive patient enrichment designs in therapeutic trials*, *Biometrical Journal* 51(2):358-374. doi: 10.1002/bimj.200900003
- [Wang *et al.* (2011)] Wang S-J *et al.* (2011) *Genomic classifier for patient enrichment: misclassification and type I error issues in pharmacogenomics noninferiority trial*, *Statistics in Biopharmaceutical Research* 3:310-319. doi: 10.1198/sbr.2010.10012
- [Wang *et al.* (2018)] Wang W *et al.* (2018) *On enrichment strategies for biomarker stratified clinical trials*, *Journal of Biopharmaceutical Statistics* 28:292-308. doi: 10.1080/10543406.2017.1379532
- [Wang *et al.* (2020)] Wang T *et al.* (2020) *Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment*, *Journal of Biopharmaceutical Statistics* 30:1060-1076. doi: 10.1080/10543406.2020.1832110
- [Wang and Hung (2013)] Wang S-J and Hung H (2013) *Adaptive enrichment with subpopulation selection at interim: methodologies, applications and design considerations*, *Contemporary Clinical Trials* 36:673-681. doi: 10.1016/j.cct.2013.09.008
- [Xu *et al.* (2020)] Xu Y *et al.* (2020) *ASIED: a Bayesian adaptive subgroup identification enrichment design*, *Journal of Biopharmaceutical Statistics* 30:623-638. doi: 10.1080/10543406.2019.16963560
- [Zeng and Breheny (2016)] Zeng Y and Breheny P (2016) *Overlapping group logistic regression with applications to genetic pathway selection*, *Cancer Informatics* 15:179-187. doi: 10.4137/CIN.S40043
- [Zhang *et al.* (2017)] Zhang Z *et al.* (2017) *Subgroup selection in adaptive signature designs of confirmatory clinical trial*, *Applied Statistics Series C* 66:345-361. doi: 10.1111/rssc.12175